Zimmer Awarded Premium Pricing for Trabecular Metal™ Modular Cup in Japan

WARSAW, Ind., Dec. 13, 2010 /PRNewswire/ — Zimmer Holdings, Inc. (NYSE: ZMH;

SIX: ZMH), a global leader in musculoskeletal care, announced today that the
Trabecular Metal Modular Cup has received the distinction of being awarded the
highest reimbursement premium percentage granted to-date for an orthopaedic
product in Japan.

The Japanese Central Social Insurance Medical Council, otherwise known as the
Chuikyo, awarded Zimmer’s Trabecular MetalModular Cup with an unprecedented 20
percent reimbursement premium. The decision was presented by the Chuikyo expert
panel after a comprehensive review of both the material technology and clinical
data. It was the opinion of the expert panel that the extensive positive
clinical data clearly demonstrated significant clinical advantages and
effectiveness of Zimmer’s proprietary Trabecular Metal Technology. Based on the
review, a new functional reimbursement category has been established in Japan
for the Trabecular Metal Modular Cup and will be introduced on January 1, 2011.

Trabecular Metal material is a highly porous biomaterial that resembles the
structure, function, and physiology of trabecular bone. No other porous metal
material is supported by the amount of peer-reviewed, published clinical data of
Trabecular Metal Technology and its history of proven success in orthopaedic
applications. This novel material is conducive to bone formation, enabling
robust biologic fixation and a stiffness similar to cancellous bone. The
properties of Trabecular Metal Technology allow for decreased stress shielding
and the material has the potential to improve long-term implant fixation.

“We believe Trabecular Metal technology represents one of the most significant
material advancements in orthopaedics, contributing both outstanding clinical
advantages and cost effectiveness to implants,” said Cheryl R. Blanchard, PhD,
Zimmer’s Senior Vice President and Chief Scientific Officer. “Securing this
reimbursement and its unprecedented premium level is a major achievement for
Zimmer. Japan is the world’s second largest orthopaedics market after the United
States and we are excited to provide the unique advantages of our Trabecular
Metaltechnology to the patients of Japan.”

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops,
manufactures and markets orthopaedic reconstructive, spinal and trauma devices,
dental implants, and related surgical products. Zimmer has operations in more
than 25 countries around the world and sells products in more than 100
countries. Zimmer’s 2009 sales were approximately $4.1 billion. The Company is
supported by the efforts of more than 8,000 employees worldwide.

Website Information

We routinely post important information for investors on our website,
www.zimmer.com, in the “Investor Relations” section. We intend to use this
website as a means of disclosing material, non-public information and for
complying with our disclosure obligations under Regulation FD. Accordingly,
investors should monitor the Investor Relations section of our website, in
addition to following our press releases, SEC filings, public conference calls,
presentations and webcasts. The information contained on, or that may be
accessed through, our website is not incorporated by reference into, and is not
a part of, this document.

Zimmer Safe Harbor Statement

This press release contains forward-looking statements within the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995 based on
current expectations, estimates, forecasts and projections about the
orthopaedics industry, management’s beliefs and assumptions made by management.
Forward-looking statements may be identified by the use of forward-looking terms
such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,”
“estimates,” “projects,” “assumes,” “guides,” “targets,” “forecasts,” and
“seeks” or the negative of such terms or other variations on such terms or
comparable terminology. These statements are not guarantees of future
performance and involve risks, uncertainties and assumptions that could cause
actual outcomes and results to differ materially. For a list and description of
such risks and uncertainties, see our periodic reports filed with the U.S.
Securities and Exchange Commission. We disclaim any intention or obligation to
update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be set forth in our
periodic reports. Readers of this document are cautioned not to place undue
reliance on these forward-looking statements, since, while we believe the
assumptions on which the forward-looking statements are based are reasonable,
there can be no assurance that these forward-looking statements will prove to be
accurate. This cautionary statement is applicable to all forward-looking
statements contained in this document.